Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 7, 2013 - Issue 8
Submit an article Journal homepage
308
Views
12
CrossRef citations to date
0
Altmetric
Reviews

Surgery for Crohn’s disease and anti-TNF agents: the changing scenario

Dario SorrentinoIBD Center - Division of Gastroenterology, Virginia Tech-Carilion School of Medicine, Roanoke, VA, USA;Department of Clinical and Experimental Medical Sciences, University of Udine Medical School, Udine, ItalyCorrespondence[email protected]
,
Sandy FogelDepartment of Surgery, Virginia Tech-Carilion School of Medicine, Roanoke, VA, USA
&
Johan Van den BogaerdeUniversity of Queensland and Sunshine Coast Clinical School, Nambour, QLD, Australia
Pages 689-700 | Published online: 10 Jan 2014

References

  • Heaton LD, Ravdin IS, Blades B, Whelan TJ. President Eisenhower’s operation for regional enteritis: a footnote to history. Ann. Surg. 159, 661–666 (1964).
  • Farmer RG, Hawk WA, Turnbull RB. Indications for surgery in Crohn’s disease: analysis of 500 cases. Gastroenterology 71(2), 245–250 (1976).
  • Bernstein CN. Neoplasia in inflammatory bowel disease: surveillance and management strategies. Curr. Gastroenterol. Rep. 8(6), 513–518 (2006).
  • Fazio VW, Marchetti F, Church M et al. Effects of resection margin on the recurrence of Crohn’s disease in the small bowel: a randomized controlled trial. Ann. Surg. 224(4), 563–571 (1996).
  • Choy PY, Bissett IP, Docherty JG, Parry BR, Merrie A, Fitzgerald A. Stapled versus handsewn methods for ileocolic anastomoses. Cochrane Database Syst. Rev. (9), CD004320 (2011).
  • Nguyen SQ, Teitelbaum E, Sabnis AA, Bonaccorso A, Tabrizian P, Salky B. Laparoscopic resection for Crohn’s disease: an experience with 335 cases. Surg. Endosc. 23(10), 2380–2384 (2009).
  • DeCruz P, Kamm MA, Prideaux L, Allen PB, Desmond PV. Postoperative recurrent luminal Crohn’s disease: a systematic review. Inflamm. Bowel Dis. 18(4), 758–777 (2012).
  • Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99(4), 956–963 (1990).
  • Terdiman JP. Prevention of postoperative recurrence in Crohn’s disease. Clin. Gastroenterol. Hepatol. 6(6), 616–620 (2008).
  • Cullen G, O’Toole A, Keegan D, Sheahan K, Hyland JM, O’donoghue DP. Long-term clinical results of ileocecal resection for Crohn’s disease. Inflamm. Bowel Dis. 13(11), 1369–1373 (2002).
  • Yamamoto T. Factors affecting recurrence after surgery for Crohn’s disease. World J. Gastroenterol. 11(43), 3971–3979 (2005).
  • Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn’s disease recurrence. Aliment. Pharmacol. Ther. 35(6), 625–633 (2012).
  • Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med. 337(15), 1029–1035 (1997).
  • Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med. 357(3), 239–250 (2007).
  • Feagan BG, Panaccione R, Sandborn WJ et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology 135(5), 1493–1499 (2008).
  • Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med. 362(15), 1383–1395 (2010).
  • Ha C, Kornbluth A. Mucosal healing in inflammatory bowel disease: where do we stand? Curr. Gastroenterol. Rep. 12(6), 471–478 (2010).
  • Basilisco G, Campanini M, Cesana B, Ranzi T, Bianchi P. Risk factors for first operation in Crohn’s disease. Am. J. Gastroenterol. 84(7), 749–752 (1989).
  • Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am. J. Gastroenterol. 99(1), 91–96 (2004).
  • Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn’s disease. Gastroenterology 128(4), 862–869 (2005).
  • Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn’s disease. J. Clin. Gastroenterol. 35(2), 151–156 (2002).
  • Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126(2), 402–413 (2004).
  • Vind I, Riis L, Jess T et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am. J. Gastroenterol. 101(6), 1274–1282 (2006).
  • Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am. J. Gastroenterol. 101(1), 110–118 (2006).
  • Jones DW, Finlayson SR. Trends in surgery for Crohn’s disease in the era of infliximab. Ann. Surg. 252(2), 307–312 (2010).
  • Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm. Bowel Dis. 13(12), 1529–1535 (2007).
  • Smyth CM, Picha SB, Rathore O, Deasy J, Patchett SE, Murray FE. Increasing rates and changing patterns of hospital admissions for patients with inflammatory bowel disease in Ireland: 1996–2001. Ir. J. Med. Sci. 174(4), 28–32 (2005).
  • Cannom RR, Kaiser AM, Ault GT, Beart RW Jr, Etzioni DA. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am. Surg. 75(10), 976–980 (2009).
  • Lazarev M, Ullman T, Schraut WH, Kip KE, Saul M, Regueiro M. Small bowel resection rates in Crohn’s disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm. Bowel Dis. 16(5), 830–835 (2010).
  • Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1), 46–54 (2012).
  • Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin. Gastroenterol. Hepatol. 5(5), 597–601 (2007).
  • Colombel JF, Loftus EV Jr, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 126(1), 19–31 (2004).
  • Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317), 1541–1549 (2002).
  • Schreiber S, Campieri M, Colombel JF et al. Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001–2003. Int. J. Colorectal. Dis. 16(1), 1–11 (2001).
  • Peyrin-Biroulet L, Bigard MA, Malesci A, Danese S. Step-up and top-down approaches to the treatment of Crohn’s disease: early may already be too late. Gastroenterology 135(4), 1420–1422 (2008).
  • D’Haens GR, Panaccione R, Higgins PD et al. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am. J. Gastroenterol. 106(2), 199–212 (2011).
  • Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut 59(9), 1200–1206 (2010).
  • Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm. Bowel Dis. 8(4), 244–250 (2002).
  • Sen D, Brasington R. Tight disease control in early rheumatoid arthritis. Rheum. Dis. Clin. North Am. 38(2), 327–343 (2012).
  • Harty LC, O’Toole G, Bennett K et al. Prescription of Tumour Necrosis Factor-α antagonists is strongly associated with a reduction in hospital admissions and in musculoskeletal surgical procedures for rheumatoid arthritis based on a 16 year analysis of nationwide data. Arthritis Rheum. 64(S10), 1072 (2012).
  • Lenfant C. Shattuck lecture--clinical research to clinical practice--lost in translation? N. Engl. J. Med. 349(9), 868–874 (2003).
  • de Buck van Overstraeten A, Wolthuis A, D’Hoore A. Surgery for Crohn’s disease in the era of biologicals: a reduced need or delayed verdict? World J. Gastroenterol. 18(29), 3828–3832 (2012).
  • Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut 60(7), 930–936 (2011).
  • Karyawasam VJ, Wang RR, Middleton KL et al. Surgical resection rate of Crohn’s disease over time: the Sydney inflammatory bowel disease cohort (1942–2012). J. Gastroenterol. Hepatol. 27(S4), 108–109 (2012).
  • Araki T, Uchida K, Okita Y et al. The impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn’s disease: a single-center paired case-control study. Surg. Today doi:10.1007/s00595-013-0538-0 (2013) ( Epub ahead of print).
  • Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort. Gut 58(4), 492–500 (2009).
  • Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn’s disease: what is the actual risk? Gut 60(9), 1178–1181 (2011).
  • Frolkis AD, Dykeman J, Negrón ME et al. Risk of surgery for the inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology doi:10.1053/j.gastro.2013.07.041 (2013) ( Epub ahead of print).
  • Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn’s disease. Cochrane Database Syst. Rev. (4), CD006873 (2009).
  • Peyrin-Biroulet L, Deltenre P, Ardizzone S et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am. J. Gastroenterol. 104(8), 2089–2096 (2009).
  • Sorrentino D. State-of-the-art medical prevention of postoperative recurrence of Crohn’s disease. Nat. Rev. Gastroenterol. Hepatol. 10(7), 413–422 (2013).
  • Dayton MT. Preventing Crohn disease recurrence with drugs after ileocolectomy. An exercise in futility? Arch. Surg. 145(1), 47–48 (2010).
  • Sorrentino D, Terrosu G, Avellini C et al. Prevention of postoperative recurrence of Crohn’s disease by Infliximab. Eur. J. Gastroenterol. Hepatol. 18(4), 457–459 (2006).
  • Sorrentino D, Terrosu G, Avellini C et al. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn’s disease. Arch. Intern. Med. 167(16), 1804–1807 (2007).
  • Regueiro M, Schraut W, Baidoo L et al. Infliximab prevents Crohn’s Disease recurrence after ileal resection. Gastroenterology 136(2), 441–450 (2009).
  • Sorrentino D, Paviotti A, Terrosu G Avellini C, Geraci M, Zarifi D. Low dose maintenance therapy with Infliximab prevents postsurgical recurrence of Crohn’s disease. Clin. Gastroenterol. Hepatol. 8(7), 591–599 (2010).
  • Yoshida K, Fukunaga K, Icheuchi H et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn’s disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm. Bowel Dis. 18(9), 1617–1623 (2011).
  • Sakuraba A, Sato T, Matsukawa H et al. The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn’s disease patients: a pilot, open-labeled prospective study. Int. J. Colorectal. Dis. 27(7), 947–952 (2012).
  • Tarekegn S, Oimoen K, Zadvornova Y et al. Biologics are superior to immunomodulators in prevention of post-operative recurrence of Crohn’s disease. Gastroenterology 140(5), S592 (2011).
  • Papamichael K, Archavlis E, Lariou C, Mantzaris GJ. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn’s disease: a prospective, two-year, single center, pilot study. J. Crohns Colitis 6(9), 924–931 (2012).
  • Savarino E, Dulbecco P, Bodini G, Assandri L, Savarino V. Prevention of postoperative recurrence of Crohn’s disease by Adalimumab: a case series. Eur. J. Gastroenterol. Hepatol. 24(4), 468–470 (2012).
  • Fernandez-Blanco I, Monturiol J, Martinez B, Cara C, Taxonera C. Adalimumab in the prevention of postoperative recurrence of Crohn’s disease. Gastroenterology 138(5), S692 (2010).
  • De Cruz P, Kamm MA, Hamilton LA et al. Optimising post-operative Crohn’s disease management: best drug therapy alone versus colonoscopic monitoring with treatment step-up. The POCER study. Gastroenterology 144(5), S164 (2013).
  • Aguas M, Bastida G, Cerrillo E et al. Adalimumab in prevention of postoperative recurrence of Crohn’s disease in high-risk patients. World J. Gastroenterol. 28(32), 4391–4398 (2012).
  • Yamamoto T. Prevention of recurrence after surgery for Crohn’s disease: efficacy of infliximab. World J. Gastroenterol. 16(43), 5405–5410 (2010).
  • Borowiec AM, Fedorak RN. Predicting, treating and preventing postoperative recurrence of Crohn’s disease: the state of the field. Can. J. Gastroenterol. 25(3), 140–146 (2011).
  • Buisson A, Chevaux JB, Bommelaer G, Peyrin-Biroulet L. Diagnosis, prevention and treatment of postoperative Crohn’s disease recurrence. Dig. Liver Dis. 44 (6), 453–460 (2012).
  • Yamamoto T, Umegae S, Matsumoto K. Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn’s disease: a prospective pilot study. Inflamm. Bowel Dis. 15(10), 1460–1466 (2009).
  • Regueiro M, Kip KE, Schraut WH et al. 4.5 Yr follow-up of patients enrolled in the randomized controlled trial (RCT) of infliximab (Inf) for prevention of postoperative Crohn’s Disease (CD). Gastroenterology 138(5), S694 (2010).
  • Sorrentino D, Terrosu G, Paviotti A et al. Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn’s disease: partial benefit by infliximab--a pilot study. Dig. Dis. Sci. 57(5), 1341–1348 (2012).
  • Boueyre E, Duclos B, Yoram B et al. Efficacy of Anti-TNF on severe postoperative endoscopic recurrence in Crohn’s Disease. Gastroenterology 142(5), S660 (2012).
  • Louis E, Mary JY, Vernier-Massouille G et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142(1), 63–70 (2012).
  • Waugh AW, Garg S, Matic K et al. Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment. Pharmacol. Ther. 32(9), 1129–1134 (2010).
  • Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand. J. Gastroenterol. 47(5), 518–527 (2012).
  • Sorrentino D, Hauenstein S, Marino M et al. Low dose infliximab for prevention of postoperative recurrence of Crohn’s disease: long term follow-up and impact of infliximab trough levels and antibodies to infliximab. Gastroenterology 144(5), S777 (2013).
  • Farthing MJ. Ileal Crohn’s disease is best treated by surgery. Gut 51(1), 13–14 (2002).
  • Alos R, Hinojosa J. Timing of surgery in Crohn’s disease: a key issue in management. World J Gastroenterol. 14(36), 5532–5539 (2008).
  • Windsor AC. Ileal Crohn’s disease is best treated by surgery. Gut 51(1), 11–12 (2002).
  • Busti AJ, Hooper JS, Amaya CJ, Kazi S. Effects of perioperative anti-inflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy 25(11), 1566–1591 (2005).
  • Ali T, Yun L, Rubin D. Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease. World J. Gastroenterol. 18(3), 197–204 (2012).
  • Appau KA, Fazio VW, Shen B et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J. Gastrointest. Surg. 12(10), 1738–1744 (2008).
  • Colombel JF, Loftus EV, Tremaine WJ et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am. J. Gastroenterol. 99(5), 878–883 (2004).
  • Marchal L, D’Haens G, Van Assche G et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 19(7), 749–754 (2004).
  • Canedo J, Lee SH, Pinto R, Murad-Regadas S, Rosen L, Wexner SD. Surgical resection in Crohn’s disease: is immunosuppressive medication associated with higher postoperative infection rates? Colorectal. Dis. 13(11), 1294–1298 (2011).
  • Kasparek MS, Bruckmeier A, Beigel F et al. Infliximab does not affect postoperative complication rates in Crohn’s patients undergoing abdominal surgery. Inflamm. Bowel Dis. 18(7), 1207–1213 (2012).
  • Nasir BS, Dozois EJ, Cima RR et al. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn’s disease. J. Gastrointest. Surg. 14(12), 1859–1865 (2010).
  • Kopylov U, Ben-Horin S, Zmora O, Eliakim R, Katz LH. Anti-tumor necrosis factor and postoperative complications in Crohn’s disease: systematic review and meta-analysis. Inflamm. Bowel Dis. 18(12), 2404–2413 (2012).
  • Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J. Gastrointest. Surg. 12(10), 1730–1736 (2008).
  • Waterman M, Xu W, Dinani A et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut 62(3), 387–394 (2013).
  • Lau CC, Dubinsky M, Melmed GY et al. Higher preoperative serum biologic levels are associated with postoperative complications in Crohn’s disease patients. Gastroenterology 144(5), S190 (2013).
  • Lau CC, Dubinsky M, Melmed GY et al. Preoperative serum biologic levels do not impact postoperative outcomes in ulcerative colitis. Gastroenterology 144(5), S189–S190 (2013).
  • Regueiro M, El-Hachem S, Kip KE et al. Postoperative infliximab is not associated with an increase in adverse events in Crohn’s disease. Dig. Dis. Sci. 56(12), 3610–3615 (2011).
  • Yang Z, Wu Q, Wang F, Wu K, Fan D. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment. Pharmacol. Ther. 36(10), 922–928 (2012).
  • Ternant D, Aubourg A, Magdelaine-Beuzelin C et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther. Drug Monit. 30(4), 523–529 (2008).
  • Ferrante M, D’Hoore A, Vermeire S et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm. Bowel Dis. 15(7), 1062–1070 (2009).
  • Sorrentino D. Role of biologics and other therapies in stricturing Crohn’s disease: what have we learnt so far? Digestion 77(1), 38–47 (2008).
  • Galandiuk S, Kimberling J, Al-Mishlab TG, Stromberg AJ. Perianal Crohn disease: predictors of need for permanent diversion. Ann. Surg. 241(5), 796–801 (2005).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.